| Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up. | |
| | |
MedLine Citation:
|
PMID: 20151211 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: The serum level of the S-100B protein is increasingly used as a tumor marker in melanoma patients. The aims of this study were to assess the clinical relevance of increased S-100B during follow up of high-risk melanoma patients and to determine the value of subsequent whole-body PET/CT and brain MRI. MATERIALS AND METHODS: A retrospective analysis was performed of all 46 melanoma patients with a normal history and physical examination who were found to have an elevated serum S-100B level (> or =0.10 microg/L) during follow-up between August 2006 and March 2009. Suspicious lesions on FDG PET/CT were biopsied for histological or cytological confirmation or were imaged further and followed if no pathology confirmation could be obtained. RESULTS: The positive predictive value of an elevated serum S-100B was 50%. PET/CT revealed hypermetabolic lesions in 27 of the 46 patients (59%). PET/CT was never false negative as confirmed by median follow-up of 1 year but was false positive in 4 patients. MRI revealed brain metastases in 1 patient (2%). Of the 23 patients with a true positive PET/CT scan, 6 (26%) received surgical treatment with curative intent; the other 17 (74%) received palliative treatment or supportive care. The survival of patients with a normal PET/CT was longer than patients with a positive PET/CT (P = .002). CONCLUSIONS: An elevated serum S-100B during follow-up of high-risk melanoma patients has a modest 50% positive predictive value for recurrent disease. Subsequent PET/CT and MRI can identify patients with recurrent disease. |
| | |
Authors:
|
Tjeerd S Aukema; Renato A Valdés Olmos; Catharina M Korse; Bin B R Kroon; Michel W J M Wouters; Wouter V Vogel; Johannes M G Bonfrer; Omgo E Nieweg |
Publication Detail:
|
Type: Journal Article Date: 2010-02-12 |
Journal Detail:
|
Title: Annals of surgical oncology Volume: 17 ISSN: 1534-4681 ISO Abbreviation: Ann. Surg. Oncol. Publication Date: 2010 Jun |
Date Detail:
|
Created Date: 2010-05-12 Completed Date: 2010-09-03 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9420840 Medline TA: Ann Surg Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 1657-61 Citation Subset: IM |
Affiliation:
|
Department of Nuclear Medicine, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. t.aukema@nki.nl |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Aged, 80 and over Brain Neoplasms / blood, diagnosis*, secondary Fluorodeoxyglucose F18 / diagnostic use Follow-Up Studies Humans Magnetic Resonance Imaging* Melanoma / blood, diagnosis*, secondary Middle Aged Nerve Growth Factors / blood* Positron-Emission Tomography* / methods Predictive Value of Tests Radiopharmaceuticals / diagnostic use Retrospective Studies S100 Proteins / blood* Sensitivity and Specificity Skin Neoplasms / blood, diagnosis*, pathology Tomography, X-Ray Computed* Tumor Markers, Biological / blood* Whole Body Imaging |
| Chemical | |
Reg. No./Substance:
|
0/Nerve Growth Factors; 0/Radiopharmaceuticals; 0/S-100 calcium-binding protein beta subunit; 0/S100 Proteins; 0/Tumor Markers, Biological; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Efficacy of a novel sphingosine kinase inhibitor in experimental Crohn's disease.
Next Document: Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure...